Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

James Uyeki (NPI 1124187927)

Field	Value
Entity Type	Individual
Organization	James Uyeki
Address	4101 James Casey St Ste 100
City	Austin
State	TX
ZIP	78745
Taxonomy	Medical Oncology Physician
NPI Enumerated	December 7, 2006

Payer Source	Total Paid
Medicare	$6.7M
Medicaid	$0

Key Findings

This provider is effectively an oncology infusion practice driven by high-volume immune checkpoint inhibitors and monoclonal antibodies: the top three Medicare revenue codes are J9271 (pembrolizumab) with 67.7K claims, $43 avg paid/claim, $2.9M revenue (45.4%); J9299 (nivolumab) with 55K claims, $24 avg paid/claim, $1.3M revenue (20.6%); and J9144 (daratumumab) with 24.1K claims, $38 avg paid/claim, $916.6K revenue (14.3%). Together these three codes account for 80.2% of the provider's Medicare revenue, indicating the practice’s service line is highly concentrated in high-cost oncology biologics and immunotherapy.

Revenue concentration is extreme: the precomputed top-3 share of 80.2% shows most Medicare dollars come from a very small set of drugs, with J9271 alone representing $2.9M (45.4%) of the $6.7M total Medicare revenue. This concentration suggests the provider’s financial performance is highly sensitive to utilization and reimbursement changes for a few specific agents.

The provider’s competitive standing on key agents is national-scale and heavily skewed: J9271 ranks #6 of 1841 providers nationally (100th percentile; extreme outlier) and J9299 ranks #7 of 505 providers nationally (99th percentile; extreme outlier), indicating this clinician is a major national billing outlier for checkpoint inhibitor administration. J9144 ranks #32 of 615 providers nationally (94th percentile; notably above typical national volume), so the practice also sits well above peers for other high-cost oncology infusions.

Administration and infusion throughput measures reinforce a high-volume infusion operation: chemotherapy administration code 96413 shows 1.2K claims, $107 avg paid/claim, $126.8K revenue and ranks #37 of 7514 providers nationally (100th percentile; extreme outlier), while add-on and follow-up infusion codes such as 96417 (307 claims) and 96367 (846 claims) rank in very high percentiles. These high percentiles for administration codes are consistent with a practice that both prescribes and delivers complex parenteral oncology therapies on-site.

The mix of supportive and ancillary drug codes—J2506 (pegfilgrastim, 972 claims), J0897 (denosumab, 15K claims), and J1568 (immune globulin, 5.7K claims)—along with in-office labs (80053, 36415, 85025) indicates the practice provides integrated oncology care including growth-factor support, bone-targeted therapy, IVIG use, and on-site phlebotomy and lab testing. This breadth of therapeutic and diagnostic codes suggests a consolidated care model where drug administration and related supportive services are centralized.

Payer mix is effectively single-payer Medicare: Total Medicare revenue is $6.7M while Total Medicaid revenue is none (no Medicaid billing on file), so the practice operates without a Medicaid billing footprint. That lack of Medicaid activity may reflect patient panel demographics, site-of-care contracting, or credentialing choices and could affect payer diversification and access to lower-income patient segments.

Tenure and operational experience are substantial: the provider’s NPI was enumerated on 2006-12-07 (~20 years ago), indicating long-standing practice presence which is consistent with the large cumulative Medicare billing volumes observed for high-cost oncology drugs. Long tenure combined with extreme national ranking on multiple agents suggests an established referral or infusion hub.

While many individual drug codes are extreme or notably above typical national volumes, other codes appear typical or unremarkable in volume (for example J1568 ranks #77 of 381 providers nationally, 80th percentile, and several lab and phlebotomy codes sit in high but not outlier percentiles). This pattern indicates a dominant focus on a few high-revenue biologics together with a normal complement of supportive and diagnostic services rather than a broad-based expansion across many disparate procedure lines.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

97 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	67,700	$40	$2.9M
J9299	Injection, nivolumab, 1 mg	54,960	$20	$1.3M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	24,120	$40	$916.6K
J0897	Injection, denosumab, 1 mg	15,000	$20	$270K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,680	$30	$193.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,190	$110	$126.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	4,090	$20	$90K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	840	$100	$80.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	970	$80	$78.7K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	190	$350	$66.7K

Showing 1–10 of 97

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 97 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

James Uyeki — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

97 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	230	10,700	$40	$516.5K
J9299	2	30	8,800	$20	$340.2K
J9144	1	30	5,850	$40	$244.6K
J1568	16	80	2,730	$30	$138.7K
J0897	18	650	2,580	$20	$79.2K
J3490	39	350	60	$480	$54.4K
Q5118	19	30	1,870	$20	$49.7K
78815	350	600	40	$460	$47.5K
Q5119	1	30	1,530	$20	$43.3K
J9305	1	10	3,380	$10	$39.3K

Showing 1–10 of 97

Related Providers

Other providers that share a Tax Identification Number (TIN) with James Uyeki, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Brennen Cheek	TX	Radiation Oncology Physician	$5.9M	$0
Joel Lurie	TX	Nurse Practitioner	$2.8M	$0
Sreedevi Daggubati	TX	Hematology & Oncology Physician	$2.8M	$0
Robert Berryman	TX	Medical Oncology Physician	$2.7M	$0
David Dspain	TX	Medical Oncology Physician	$2.6M	$0
Darren Kocs	TX	Hematology & Oncology Physician	$2.5M	$0
Dina Tebcherany	TX	Medical Oncology Physician	$2.5M	$0
Srini Reddy	TX	Hematology & Oncology Physician	$2.5M	$0
Thomas Gregory	TX	Medical Oncology Physician	$2.4M	$0
Praveen Tumula	TX	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as James Uyeki, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
American Medical Response Of Texas Inc	TX	Ambulance	$2.9M	$4.1M
Rene Castillo	TX	Medical Oncology Physician	$2M	$0
Blakely Richardson	TX	Dermatology Physician	$1.4M	$0
South Austin Surgery Center Ltd	TX	Ambulatory Surgical Clinic/Center	$1.1M	$297.7K
Abigail Owunna	TX	Family Nurse Practitioner	$1.2M	$0
Ryan Tierney	TX	Radiation Oncology Physician	$1.2M	$0
Stonegate Surgery Center LP	TX	Ambulatory Surgical Clinic/Center	$1.1M	$0
Austin Gi Surgicenter, LLC	TX	Ambulatory Surgical Clinic/Center	$978.1K	$0
Ara/st. David's Imaging, LP	TX	Radiology Clinic/Center	$734.9K	$1.6K
Steven Dobberfuhl	TX	Internal Medicine Physician	$648.5K	$0

James Uyeki — Billing Profile & Reimbursement Data

Sign up for James Uyeki — Billing Profile & Reimbursement Data policy alerts

James Uyeki — Billing Profile & Reimbursement Data

Sign up for James Uyeki — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References